AUTHORS
Kiana Kalei Kaumaka Guillermo, MSc, Krista Tsai2, Lucas Wadley, PhD, BS3, Dominik Wodarz, PhD4, Natalia Komarova, PhD5, Angela Fleischman, MD, PhD6
AFFILIATIONS
1 University of California, Irvine, Irvine, California, United States
2 University of California, Irvine, Irvine, California, United States
3 University of California, Irvine, Irvine, California, United States
4 University of California, Irvine, Irvine, California, United States
5 University of California, Irvine, Irvine, California, United States
6 University of California, Irvine, Irvine, California, United States
ABSTRACT
Aging hematopoietic stem cells (HSCs) compete for clonal dominance within the bone marrow, an ecosystem where fitness determines outgrowth. Mutations in epigenetic regulators such as DNMT3A and TET2 are common drivers of this competition, producing clonal hematopoiesis of indeterminate potential (CHIP) in older adults. While CHIP increases risk of hematologic malignancy, most carriers never progress to disease. Clonal expansion depends on both intrinsic HSC fitness and external pressures like inflammation, but most experimental models pit a single mutant clone against wild type (WT) rather than reflecting the multiclonal reality of aged marrow. We applied an ecological framework to this problem, hypothesizing that a highly fit but low oncogenic clone could buffer against outgrowth of a malignant clone.
To test this, we competed Tet2-/- (high fitness, low oncogenic potential) and Jak2V617F (a driver of myeloproliferative neoplasm, MPN) whole bone marrow across three transplant scenarios.
First, Tet2-/- or WT CD45.1 marrow competed against Jak2V617F CD45.2 marrow at equal ratio in lethally irradiated recipients. Jak2V617F paired with WT produced erythrocytosis consistent with polycythemia vera, while Jak2V617F paired with Tet2-/- did not. By day 36, Jak2V617F donor chimerism was 26% with WT competitors versus 11% with Tet2-/- competitors (p=0.01), and this gap widened over the transplant course. At sacrifice (D207), Jak2V617F contribution was significantly lower across all stem and progenitor populations in Tet2-/- competitors, for example 72% of donor derived cells in WT competitors versus 7% in Tet2-/- competitors within the HSC population.
Second, we modeled resident CHIP preventing a later malignant clone. Tet2-/- or WT marrow was allowed to reconstitute for two months, then minimally irradiated recipients were seeded with Jak2V617F marrow. Jak2V617F engrafted without expanding in Tet2-/- hosts but expanded in WT hosts, which alone developed erythrocytosis, megakaryocyte hyperplasia, and splenomegaly. Secondary transplants confirmed Tet2-/- competitor marrow carried no latent MPN initiating capacity, unlike WT.
Third, we modeled Tet2-/- cells as an intervention after MPN was established. Jak2V617F marrow was allowed to reconstitute, then minimally irradiated recipients received WT or Tet2-/- marrow. Tet2-/- cells expanded more robustly than WT and reduced Jak2V617F chimerism to 7% versus 62% with WT. Preexisting erythrocytosis resolved after Tet2-/- introduction but persisted with WT.
Mathematical modeling of the transplant data gave a consistent fitness ordering, Jak2V617F less than WT less than Tet2-/-. During the repopulation growth phase, WT held a selection coefficient of 0.027 per day over Jak2V617F, Tet2-/- held 0.043 per day over WT, and Tet2-/- held 0.056 per day over Jak2V617F. A logistic steady state fit gave a selection coefficient of 0.025 per day for Jak2V617F over WT. Simulations across a range of assumed Tet2-/- fitness advantages showed that sufficient advantage suppresses Jak2V617F outgrowth in both prevention and intervention settings, recapitulating the transplant data.
To probe mechanism, we performed a competitive transplant for RNA sequencing, pitting Jak2V617F or WT CD45.1 marrow against Tet2-/- or WT CD45.1/2 marrow at a 90 to 10 ratio, harvested three months post-transplant. WT and Jak2V617F bystander cells exposed to Tet2-/- showed enrichment for IFNα, IFNγ, and inflammatory response pathways, along with Myc and E2F targets. IFNα is the only therapy shown to reduce Jak2V617F clonal burden through exhaustion of mutant HSCs, suggesting Tet2-/- competitors suppress Jak2V617F via an induced interferon response.
Together, these data show that a clone with high competitive fitness and low oncogenic potential can outcompete an MPN driver clone and reduce MPN phenotype, offering proof of concept that engineering competitor clone composition could steer hematopoiesis toward a benign outcome.
DISCLOSURES
Kiana Kalei Kaumaka Guillermo, MSc: No relevant conflicts of interest to declare.